The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants
Gershengorn et al.,
The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants,
PLOS ONE, doi:10.1371/journal.pone.0278770
Retrospective 2,083 outpatients in the USA, showing higher risk of hospitalization with casirivimab/imdevimab, without statistical significance. There may be significant unadjusted
confounding by indication.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted
confounding by indication possible.
risk of hospitalization, 95.0% higher, OR 1.95, p = 0.09, treatment 369, control 5,915, adjusted per study, multivariable, day 30, RR approximated with OR.
|
risk of hospitalization, 104.9% higher, RR 2.05, p = 0.009, treatment 21 of 369 (5.7%), control 41 of 1,476 (2.8%), propensity score matching, day 30, Figure 2, PSM cohort.
|
risk of hospitalization, 100% higher, RR 2.00, p = 0.07, treatment 11 of 213 (5.2%), control 22 of 852 (2.6%), delta, propensity score matching, day 30, Figure 2, PSM cohort.
|
risk of hospitalization, 110.5% higher, RR 2.11, p = 0.06, treatment 10 of 156 (6.4%), control 19 of 624 (3.0%), omicron, propensity score matching, day 30, Figure 2, PSM cohort.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Gershengorn et al., 2 Dec 2022, retrospective, USA, peer-reviewed, 6 authors.
Contact:
hbg20@med.miami.edu, hsro@miami.edu.
Abstract: PLOS ONE
RESEARCH ARTICLE
The clinical effectiveness of REGEN-COV in
SARS-CoV-2 infection with Omicron versus
Delta variants
Hayley B. Gershengorn ID1,2*, Samira Patel3, Tanira Ferreira1, Sankalp Das3, Dipen
J. Parekh4, Bhavarth Shukla5
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
1 Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Miami
Miller School of Medicine, Miami, FL, United States of America, 2 Division of Critical Care Medicine, Albert
Einstein College of Medicine, Bronx, NY, United States of America, 3 Care Transformation, University of
Miami Hospital and Clinics, Miami, FL, United States of America, 4 Department of Urology, University of
Miami Miller School of Medicine, Miami, FL, United States of America, 5 Division of Infectious Diseases,
Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, United States of America
* hbg20@med.miami.edu
Abstract
OPEN ACCESS
Background
Citation: Gershengorn HB, Patel S, Ferreira T, Das
S, Parekh DJ, Shukla B (2022) The clinical
effectiveness of REGEN-COV in SARS-CoV-2
infection with Omicron versus Delta variants. PLoS
ONE 17(12): e0278770. https://doi.org/10.1371/
journal.pone.0278770
In vitro studies suggesting that REGEN-COV (casirivimab plus imdevimab monoclonal antibodies) had poor efficacy against Omicron-variant SARS-CoV-2 infection led to amendment of
REGEN-COV’s Emergency Use Authorization to recommend use only in regions without high
Omicron prevalence. REGEN-COV’s relative clinical effectiveness for Omicron is unknown.
Editor: Vipa Thanachartwet, Mahidol University,
Faculty of Tropical Medicine, THAILAND
Methods and findings
Received: July 26, 2022
Accepted: November 23, 2022
Published: December 2, 2022
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0278770
Copyright: © 2022 Gershengorn et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data cannot be
shared publicly because of HIPAA. Data are
available from the University of Miami Institutional
Data Access / Ethics Committee (contact via
We conducted a retrospective cohort study of non-hospitalized adults who tested positive
for SARS-CoV-2 by polymerase chain reaction at the University of Miami Health System
from July 19 –November 21, 2021 (Delta period) and December 6, 2021 –January 7, 2022
(Omicron period). Subjects were stratified be REGEN-COV receipt within 72h of test positivity and by time period of infection. We constructed multivariable logistic regression models
to assess the differential association of REGEN-COV receipt with hospitalization within 30
days (primary outcome) and ED presentation; all models included three exposure terms
(REGEN-COV receipt, Omicron vs Delta period, interaction of REGEN-COV with time
period) and potential confounders (vaccination status, vaccine boosting, cancer diagnosis).
Our cohort consisted of 2,083 adults in the Delta period (213 [10.2%] received REGENCOV) and 4,201 in the Omicron period (156 [3.7%]..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit